GlobalData on MSN18h
GenSight’s Optic Neuropathy gene therapy sustains efficacy over five yearsThe five-year trial saw patients who received a single injection of Lumevoq sustaining clinical recovery in a rare condition that can lead to blindness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback